OPEN END TURBO OHNE STOP-LOSS - NOVO-NORDISK B | Market Closed - Börse Stuttgart 07:11:55 05/07/2024 BST | ||
| 1.03 EUR | +1.98% |
|
| Current month | -10.43% | ||
| 1 month | +0.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.03 | +1.98% |
| 04/07/24 | 1.01 | -6.48% |
| 03/07/24 | 1.08 | -6.90% |
| 02/07/24 | 1.16 | +2.65% |
| 01/07/24 | 1.13 | -1.74% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:11 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Lang & Schwarz |
| WKN | LX3CUR |
| ISIN | DE000LX3CUR9 |
| Date issued | 10/08/2023 |
| Strike | 77.59 € |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.17 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
